EA025532B1 - Способ выделения клеток-предшественников из человеческой пуповины - Google Patents
Способ выделения клеток-предшественников из человеческой пуповины Download PDFInfo
- Publication number
- EA025532B1 EA025532B1 EA201000425A EA201000425A EA025532B1 EA 025532 B1 EA025532 B1 EA 025532B1 EA 201000425 A EA201000425 A EA 201000425A EA 201000425 A EA201000425 A EA 201000425A EA 025532 B1 EA025532 B1 EA 025532B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cells
- umbilical cord
- flask
- specified
- cell
- Prior art date
Links
- 210000003954 umbilical cord Anatomy 0.000 title claims abstract description 72
- 238000000034 method Methods 0.000 title claims abstract description 58
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 41
- 210000004027 cell Anatomy 0.000 claims abstract description 312
- 239000002243 precursor Substances 0.000 claims abstract description 16
- 239000002537 cosmetic Substances 0.000 claims abstract description 4
- 210000001519 tissue Anatomy 0.000 claims description 61
- 238000003776 cleavage reaction Methods 0.000 claims description 59
- 230000007017 scission Effects 0.000 claims description 51
- 238000011534 incubation Methods 0.000 claims description 32
- 239000012634 fragment Substances 0.000 claims description 31
- 238000002955 isolation Methods 0.000 claims description 27
- 238000005138 cryopreservation Methods 0.000 claims description 21
- 230000004069 differentiation Effects 0.000 claims description 19
- 208000007536 Thrombosis Diseases 0.000 claims description 17
- 102000029816 Collagenase Human genes 0.000 claims description 16
- 108060005980 Collagenase Proteins 0.000 claims description 16
- 229960002424 collagenase Drugs 0.000 claims description 16
- 108090000631 Trypsin Proteins 0.000 claims description 15
- 102000004142 Trypsin Human genes 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 239000012588 trypsin Substances 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 14
- 230000002255 enzymatic effect Effects 0.000 claims description 10
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 9
- 210000001691 amnion Anatomy 0.000 claims description 8
- 210000001789 adipocyte Anatomy 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 210000002569 neuron Anatomy 0.000 claims description 7
- 210000000963 osteoblast Anatomy 0.000 claims description 7
- 210000001612 chondrocyte Anatomy 0.000 claims description 6
- 239000008188 pellet Substances 0.000 claims description 6
- 230000003068 static effect Effects 0.000 claims description 6
- 210000004498 neuroglial cell Anatomy 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 4
- 239000013049 sediment Substances 0.000 claims description 3
- 210000001074 muscle attachment cell Anatomy 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims 13
- 230000001464 adherent effect Effects 0.000 claims 2
- 238000009395 breeding Methods 0.000 claims 2
- 230000001488 breeding effect Effects 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 230000000644 propagated effect Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 210000003372 endocrine gland Anatomy 0.000 claims 1
- 210000004920 epithelial cell of skin Anatomy 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 210000000442 hair follicle cell Anatomy 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 210000002363 skeletal muscle cell Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 230000012010 growth Effects 0.000 abstract description 32
- 238000002659 cell therapy Methods 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000007710 freezing Methods 0.000 abstract description 3
- 230000008014 freezing Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000003908 quality control method Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 47
- 239000012071 phase Substances 0.000 description 46
- 239000002609 medium Substances 0.000 description 45
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 34
- 239000001963 growth medium Substances 0.000 description 31
- 102000004190 Enzymes Human genes 0.000 description 22
- 108090000790 Enzymes Proteins 0.000 description 22
- 229940088598 enzyme Drugs 0.000 description 22
- 229930182555 Penicillin Natural products 0.000 description 17
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 17
- 229940049954 penicillin Drugs 0.000 description 17
- 229960005322 streptomycin Drugs 0.000 description 17
- 239000006285 cell suspension Substances 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 12
- 238000005457 optimization Methods 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 238000005119 centrifugation Methods 0.000 description 11
- 239000012894 fetal calf serum Substances 0.000 description 11
- 238000010257 thawing Methods 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
- 239000007640 basal medium Substances 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000009816 chondrogenic differentiation Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 229930182816 L-glutamine Natural products 0.000 description 6
- 108010059712 Pronase Proteins 0.000 description 6
- 230000009815 adipogenic differentiation Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 238000010494 dissociation reaction Methods 0.000 description 6
- 230000005593 dissociations Effects 0.000 description 6
- 230000002518 glial effect Effects 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000012808 vapor phase Substances 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 108010004729 Phycoerythrin Proteins 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 230000001625 cardiomyogenic effect Effects 0.000 description 5
- 230000006862 enzymatic digestion Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 230000009818 osteogenic differentiation Effects 0.000 description 5
- 230000020477 pH reduction Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 4
- 108010003272 Hyaluronate lyase Proteins 0.000 description 4
- 102000001974 Hyaluronidases Human genes 0.000 description 4
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 102000004987 Troponin T Human genes 0.000 description 4
- 108090001108 Troponin T Proteins 0.000 description 4
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000005549 deoxyribonucleoside Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 229960002773 hyaluronidase Drugs 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 238000007747 plating Methods 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 239000002342 ribonucleoside Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 208000036815 beta tubulin Diseases 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000011162 core material Substances 0.000 description 3
- 239000005547 deoxyribonucleotide Substances 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 230000001272 neurogenic effect Effects 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 101000613243 Gadus morhua Trypsin-10 Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000002803 maceration Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- MZIYRTZAYQIAHW-UHFFFAOYSA-N 1-methyl-8-(2-methylpropyl)-3,7-dihydropurine-2,6-dione Chemical compound N1C(=O)N(C)C(=O)C2=C1N=C(CC(C)C)N2 MZIYRTZAYQIAHW-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 102100024482 Cell division cycle-associated protein 4 Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000980898 Homo sapiens Cell division cycle-associated protein 4 Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 101150025129 POP1 gene Proteins 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011536 re-plating Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0604—Whole embryos; Culture medium therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT103843A PT103843B (pt) | 2007-10-04 | 2007-10-04 | Método de isolamento de células precursoras a partir do cordão umbilical humano |
| PCT/IB2008/054067 WO2009044379A2 (en) | 2007-10-04 | 2008-10-03 | Optimised and defined method for isolation and preservation of precursor cells from human umbilical cord |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201000425A1 EA201000425A1 (ru) | 2010-10-29 |
| EA025532B1 true EA025532B1 (ru) | 2017-01-30 |
Family
ID=40456372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201000425A EA025532B1 (ru) | 2007-10-04 | 2008-10-03 | Способ выделения клеток-предшественников из человеческой пуповины |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9546353B2 (enExample) |
| EP (1) | EP2203555B1 (enExample) |
| JP (1) | JP5785394B2 (enExample) |
| KR (1) | KR20100087705A (enExample) |
| CN (1) | CN101868536B (enExample) |
| AU (1) | AU2008306442B2 (enExample) |
| BR (1) | BRPI0817522A2 (enExample) |
| CA (1) | CA2701907A1 (enExample) |
| EA (1) | EA025532B1 (enExample) |
| ES (1) | ES2582369T3 (enExample) |
| IL (1) | IL204788A (enExample) |
| MX (1) | MX2010003511A (enExample) |
| PT (1) | PT103843B (enExample) |
| WO (1) | WO2009044379A2 (enExample) |
| ZA (1) | ZA201002260B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2634545T3 (es) | 2010-06-01 | 2017-09-28 | Auxocell Laboratories, Inc. | Células madre nativas de la gelatina de Wharton y su purificación |
| US9234177B2 (en) | 2010-10-18 | 2016-01-12 | Sunshine Life Science & Technology Corp. | Human multipotent embryonic stem cell-like progenitor cells |
| TWI535377B (zh) * | 2011-09-01 | 2016-06-01 | Storage, culture and application of umbilical cord tissue and its derived cells | |
| ES2890126T3 (es) * | 2011-12-30 | 2022-01-17 | Amit Patel | Métodos y composiciones para la obtención clínica de una célula alogénica y usos terapéuticos |
| CN102550543B (zh) * | 2012-02-10 | 2014-04-16 | 四川新生命干细胞科技股份有限公司 | 用于保存脐带组织的液体 |
| CN103461322B (zh) * | 2012-06-07 | 2016-08-03 | 西比曼生物科技（上海）有限公司 | 用于冻存复苏后的细胞的保存液 |
| EP2756754B1 (de) | 2013-01-17 | 2017-01-04 | Vita 34 Ag | Verfahren zur Behandlung von Nabelschnurgewebe, insbesondere im Zusammenhang mit der Konservierung des Gewebes |
| WO2015181831A2 (en) * | 2014-05-24 | 2015-12-03 | Venkataramanaa Neelamkrishnan | A method for targettingglioblastoma with wharton jelly-mesenchymal stem cells (wj-msc) derived from human umbilical cord |
| JP2017533917A (ja) * | 2014-11-05 | 2017-11-16 | ティッシュテック，インク． | 神経成長および再生を促進するための組成物および方法 |
| WO2017004460A1 (en) * | 2015-06-30 | 2017-01-05 | Surgenex, LLC | Compositions and methods for flowable allograft tissue |
| WO2017096611A1 (zh) * | 2015-12-11 | 2017-06-15 | 郭镭 | 一种从脐带华通氏胶组织中分离培养脐带间充质干细胞的方法 |
| WO2019175773A1 (en) | 2018-03-12 | 2019-09-19 | Universidade Do Porto | Compositions for use in the treatment of musculoskeletal conditions and methods for producing the same leveraging the synergistic activity of two different types of mesenchymal stromal/stem cells |
| CN112342191A (zh) * | 2019-08-07 | 2021-02-09 | 路春光 | hMSC生产试剂盒开发和质量管理标准优化和体系建立 |
| CN111893092A (zh) * | 2020-06-28 | 2020-11-06 | 国大生命科学产业集团(深圳)有限公司 | 一种人脐带来源的间充质干细胞及其制备方法 |
| CN113025567A (zh) * | 2021-03-31 | 2021-06-25 | 中国人民解放军陆军特色医学中心 | 一种椎间盘单细胞的分离方法 |
| DE102021116694B4 (de) * | 2021-06-29 | 2023-03-09 | Promocell Gmbh | Wässrige Lösung zur Zellkonservierung |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT402890B (de) * | 1994-03-16 | 1997-09-25 | Berbi Gmbh | Verwendung von notoginsenosid r1 zur herstellung von arzneimitteln |
| JPWO2003080822A1 (ja) * | 2002-03-27 | 2005-07-28 | ニプロ株式会社 | 胎盤由来の間葉系細胞およびその医学的用途 |
| CA2633980A1 (en) * | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Improved composition for collecting and preserving placental stem cells and methods of using the composition |
| ES2524443T3 (es) * | 2006-11-13 | 2014-12-09 | DePuy Synthes Products, LLC | Expansión in vitro de células postparto usando microportadores |
-
2007
- 2007-10-04 PT PT103843A patent/PT103843B/pt active IP Right Grant
-
2008
- 2008-10-03 CA CA2701907A patent/CA2701907A1/en not_active Abandoned
- 2008-10-03 KR KR1020107009850A patent/KR20100087705A/ko not_active Ceased
- 2008-10-03 MX MX2010003511A patent/MX2010003511A/es active IP Right Grant
- 2008-10-03 JP JP2010527592A patent/JP5785394B2/ja not_active Expired - Fee Related
- 2008-10-03 WO PCT/IB2008/054067 patent/WO2009044379A2/en not_active Ceased
- 2008-10-03 US US12/680,604 patent/US9546353B2/en not_active Expired - Fee Related
- 2008-10-03 EP EP08807881.1A patent/EP2203555B1/en not_active Not-in-force
- 2008-10-03 ES ES08807881.1T patent/ES2582369T3/es active Active
- 2008-10-03 EA EA201000425A patent/EA025532B1/ru not_active IP Right Cessation
- 2008-10-03 BR BRPI0817522-5A2A patent/BRPI0817522A2/pt not_active Application Discontinuation
- 2008-10-03 AU AU2008306442A patent/AU2008306442B2/en not_active Ceased
- 2008-10-03 CN CN200880114557.0A patent/CN101868536B/zh not_active Expired - Fee Related
-
2010
- 2010-03-28 IL IL204788A patent/IL204788A/en not_active IP Right Cessation
- 2010-03-30 ZA ZA2010/02260A patent/ZA201002260B/en unknown
Non-Patent Citations (3)
| Title |
|---|
| CAN ALP, KARAHUSEYINOGLU S: "Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells.", STEM CELLS, ALPHAMED PRESS, INC., UNITED STATES, vol. 25, no. 11, United States, pages 2886 - 2895, XP002521370, ISSN: 1549-4918, DOI: 10.1634/STEMCELLS.2007-0417 * |
| LU LU-LU; LIU YONG-JUN; YANG SHAO-GUANG; ZHAO QIN-JUN; WANG XIN; GONG WEI; HAN ZHI-BO; XU ZHEN-SHU; LU YONG-XIN; LIU DELONG; CHEN : "Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials", HAEMATOLOGICA, THE HEMATOLOGY JOURNAL : OFFICIAL ORGAN OF THE EUROPEAN HEMATOLOGY ASSOCIATION, FONDAZIONE FERRATA STORTI, IT, vol. 91, no. 8, 1 August 2006 (2006-08-01), IT, pages 1017 - 1026, XP009110905, ISSN: 0390-6078 * |
| WEISS MARK L ET AL: "Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease.", STEM CELLS., ALPHAMED PRESS, DAYTON, OH., US, vol. 24, no. 3, 1 March 2006 (2006-03-01), US, pages 781 - 792, XP002463574, ISSN: 1066-5099, DOI: 10.1634/stemcells.2005-0330 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010003511A (es) | 2010-09-10 |
| JP2010539970A (ja) | 2010-12-24 |
| JP5785394B2 (ja) | 2015-09-30 |
| AU2008306442B2 (en) | 2014-12-04 |
| EP2203555A2 (en) | 2010-07-07 |
| ZA201002260B (en) | 2011-06-29 |
| ES2582369T3 (es) | 2016-09-12 |
| EA201000425A1 (ru) | 2010-10-29 |
| KR20100087705A (ko) | 2010-08-05 |
| IL204788A (en) | 2013-07-31 |
| EP2203555B1 (en) | 2016-04-13 |
| US20100216237A1 (en) | 2010-08-26 |
| CN101868536B (zh) | 2015-03-25 |
| PT103843A (pt) | 2008-01-09 |
| PT103843B (pt) | 2008-08-12 |
| CA2701907A1 (en) | 2009-04-09 |
| US9546353B2 (en) | 2017-01-17 |
| WO2009044379A2 (en) | 2009-04-09 |
| WO2009044379A3 (en) | 2009-05-22 |
| CN101868536A (zh) | 2010-10-20 |
| IL204788A0 (en) | 2010-12-30 |
| AU2008306442A1 (en) | 2009-04-09 |
| BRPI0817522A2 (pt) | 2014-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA025532B1 (ru) | Способ выделения клеток-предшественников из человеческой пуповины | |
| Ebner-Peking et al. | Self-assembly of differentiated progenitor cells facilitates spheroid human skin organoid formation and planar skin regeneration | |
| KR100489248B1 (ko) | 제대혈 유래 간엽줄기세포ㆍ전구세포의 분리배양방법 및간엽조직으로의 분화유도방법 | |
| EP2414511B1 (en) | Isolation of human umbilical cord blood-derived mesenchymal stem cells | |
| KR100870508B1 (ko) | 지방 유래 간세포 및 격자 | |
| US8481311B2 (en) | Progenitor cells from wharton's jelly of human umbilical cord | |
| US20150175970A1 (en) | Cells for therapy of the heart, method of obtaining a cell preparation, and cell preparation | |
| JPWO2005063967A1 (ja) | 哺乳動物の骨髄細胞または臍帯血由来細胞と脂肪組織を利用した心筋細胞の誘導 | |
| Dulugiac et al. | Comparative studies of mesenchymal stem cells derived from different cord tissue compartments–the influence of cryopreservation and growth media | |
| KR20100084620A (ko) | 조직 재생을 위한 세포 조성물 | |
| BR112020012436A2 (pt) | células estromais mesenquimais e métodos para obter células estromais mesenquimais do cordão umbilical | |
| Mattei et al. | Validated methods for isolation and qualification of mesenchymal stromal/stem cells from different sources | |
| Rogic et al. | Isolation of human skin lymphatic endothelial cells and 3D reconstruction of the lymphatic vasculature in vitro | |
| ES2825723T3 (es) | Método para utilizar células directoras para la activación y diferenciación de células madre/progenitoras específicas | |
| US8986678B2 (en) | Preparation of parental cell bank from foetal tissue | |
| KR20200047565A (ko) | 어린 돼지 유래 줄기 세포 및 그 제조 방법 | |
| JP2022518159A (ja) | ヒト脂肪組織幹細胞のｉｎ ｖｉｔｒｏまたはｅｘ ｖｉｖｏでの増幅方法 | |
| RU2505602C1 (ru) | Способ получения резидентных стволовых клеток сердца млекопитающего из образцов миокарда |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |